Abstract The United States Food and Drug Administration (US FDA) has always been a
forerunner in drug evaluation and supervision. Over the past 31 years, 1050 drugs …

Undruggable proteins are a class of proteins that are often characterized by large, complex
structures or functions that are difficult to interfere with using conventional drug design …

The epidermal growth factor receptor (EGFR) belongs to the ERBB family of tyrosine kinase
receptors. EGFR signaling cascade is a key regulator in cell proliferation, differentiation …

Proteolysis targeting chimera (PROTAC) technology has emerged over the last two decades
as a powerful tool for targeted degradation of endogenous proteins. Herein we describe the …

The targeting of vascular endothelial growth factor A (VEGFA), a crucial regulator of both
normal and pathological angiogenesis, has revealed innovative therapeutic approaches in …

The glycosaminoglycan hyaluronan (HA), a major component of extracellular matrices, and
cell surface receptors of HA have been proposed to have pivotal roles in cell proliferation …

Human epidermal growth factor receptor 2 (HER2) is overexpressed in> 20% of breast
cancers. Dimerization of HER2 receptors leads to the activation of downstream signals …

Excessive abnormal angiogenesis plays a pivotal role in tumor progression and is a
hallmark of solid tumors. This process is driven by an imbalance between pro-and anti …

All patients with metastatic lung, colorectal, pancreatic or head and neck cancers who
initially benefit from epidermal growth factor receptor (EGFR)-targeted therapies eventually …

Purpose: SHP2 inhibitors offer an appealing and novel approach to inhibit receptor tyrosine
kinase (RTK) signaling, which is the oncogenic driver in many tumors or is frequently …